These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29589680)

  • 1. Management of ductal carcinoma in situ in the modern era.
    Khan A; Dumitru D; Catanuto G; Rocco N; Nava MB; Benson J
    Minerva Chir; 2018 Jun; 73(3):303-313. PubMed ID: 29589680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal carcinoma in situ: a disease entity that merits more recognition.
    Dereere E; Papadimitriou K; Tjalma W; Altintas S
    Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ductal carcinoma in situ, complexities and challenges.
    Leonard GD; Swain SM
    J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in the Treatment of Ductal Carcinoma in Situ.
    Barrio AV; Van Zee KJ
    Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics.
    Schnitt SJ
    J Natl Cancer Inst Monogr; 2010; 2010(41):158-61. PubMed ID: 20956823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
    Pilewskie M; Olcese C; Patil S; Van Zee KJ
    Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less.
    Toss A; Palazzo J; Berger A; Guiles F; Sendecki JA; Simone N; Anne R; Avery T; Jaslow R; Lazar M; Tsangaris T; Cristofanilli M
    Breast; 2016 Oct; 29():223-30. PubMed ID: 27506636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.
    Martínez-Pérez C; Turnbull AK; Ekatah GE; Arthur LM; Sims AH; Thomas JS; Dixon JM
    Cancer Treat Rev; 2017 Apr; 55():163-172. PubMed ID: 28402908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The surgical management of ductal carcinoma in situ.
    Kumar S; Sacchini V
    Breast J; 2010; 16 Suppl 1():S49-52. PubMed ID: 21050311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.
    Lazzeroni M; Dunn BK; Pruneri G; Jereczek-Fossa BA; Orecchia R; Bonanni B; DeCensi A
    Cancer Treat Rev; 2017 Apr; 55():1-9. PubMed ID: 28262606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(5):217-25. PubMed ID: 14626378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Breast Cancer Audit: ductal carcinoma in situ management in Australia and New Zealand.
    Cuncins-Hearn A; Boult M; Babidge W; Zorbas H; Villanueva E; Evans A; Oliver D; Kollias J; Reeve T; Maddern G
    ANZ J Surg; 2007; 77(1-2):64-8. PubMed ID: 17295824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary treatment of ductal carcinoma in situ of the breast.
    Mokbel K
    Med Sci Monit; 2005 Mar; 11(3):RA86-93. PubMed ID: 15735580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative tamoxifen for ductal carcinoma in situ.
    Staley H; McCallum I; Bruce J
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards optimal management of ductal carcinoma in situ of the breast.
    Mokbel K
    Eur J Surg Oncol; 2003 Mar; 29(2):191-7. PubMed ID: 12633565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ductal Carcinoma In Situ: Treatment Update and Current Trends.
    Mitchell KB; Kuerer H
    Curr Oncol Rep; 2015 Nov; 17(11):48. PubMed ID: 26373411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.
    Gangi A; Topham A; Lee MC; Sun W; Laronga C
    South Med J; 2017 Oct; 110(10):649-653. PubMed ID: 28973706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.